Imagine a child diagnosed with a kidney disease, facing a lifetime of potential complications. New research is challenging the long-held belief that certain kidney diseases, specifically primary glomerular diseases, are relatively harmless in children and young adults. In fact, this groundbreaking study suggests that some young patients might actually experience faster kidney function decline than older adults with the same conditions. This alarming discovery is set to be presented at ASN Kidney Week 2025, from November 5-9, and it could change the way we approach treatment for these vulnerable patients.
But here's where it gets controversial... the study directly contradicts what many doctors have assumed for years. We're talking about diseases like minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and IgA nephropathy (IgAN) – all primary glomerular diseases. These diseases affect the glomeruli, which are tiny filters in the kidneys responsible for cleaning your blood. When these filters are damaged, it can lead to serious kidney problems.
Traditionally, comparing outcomes between adult and pediatric patients with these glomerular diseases has been difficult due to a lack of comprehensive data. That's where the CureGN study comes in. CureGN is one of the largest and most comprehensive long-term studies of glomerular diseases ever conducted. Researchers dove into the CureGN data to compare the rate of kidney function decline and the risk of progressing to severe outcomes, defined as kidney failure, a ≥40% drop in estimated glomerular filtration rate (eGFR), or even death, between different age groups. eGFR, for those unfamiliar, is a measure of how well your kidneys are filtering waste from your blood – a lower eGFR means your kidneys aren't working as well.
And this is the part most people miss... The results were startling. Children and young adults faced similar, and in some cases, even higher risks of reaching these adverse outcomes compared to older adults. For instance, pediatric patients diagnosed with MCD showed a steeper decline in eGFR compared to adult MCD patients. Furthermore, MN patients aged 13-17 and FSGS and IgA nephropathy patients aged 18-44 showed the most rapid eGFR decline within their respective diagnosis groups. Think about that for a moment – teenagers and young adults experiencing the fastest decline in kidney function!
Interestingly, when looking at the composite outcome of death, kidney failure, or a ≥40% eGFR decline, the researchers found no significant differences among age groups for patients with MCD, FSGS, and MN. However, IgA nephropathy patients aged 6-12, 13-17, and 45-64 had lower risks of progression compared to those aged 18-44. This suggests that the impact of IgA nephropathy might be different across the lifespan, and warrants further investigation.
"These findings suggest that young patients who obtained a kidney biopsy diagnosis of primary glomerular disease face significant risk of reaching kidney failure and requiring dialysis and / or a transplant in their lifetimes," explains lead author Margaret Helmuth, MS, from the University of Michigan, Ann Arbor. This isn't just about numbers; it's about the potential for a lifetime of medical interventions and reduced quality of life for these young patients.
Co-author Chia-shi Wang, MD, MSc, of the Emory University School of Medicine, emphasizes the need to include children in clinical trials for disease treatment. "Our research also highlights the importance of including children in clinical trials for disease treatment to mitigate against the adverse outcomes they face," Dr. Wang added. This is a critical point – if we want to develop effective treatments for these diseases, we need to study how they affect children specifically.
The full study, titled "Glomerular Disease Outcomes Across the Lifespan: Report of the Cure Glomerulonephropathy (CureGN) Research Consortium," will be presented at Kidney Week 2025. This research is a vital step towards understanding the long-term impact of glomerular diseases on young patients and developing strategies to improve their outcomes.
ASN Kidney Week 2025, held in Houston, TX, is expected to gather approximately 12,000 kidney professionals from around the world. It's the premier nephrology meeting, offering opportunities to exchange knowledge, learn about the latest scientific advancements, and engage in discussions with leading experts. Early programs begin on November 5, with the Annual Meeting running from November 6-9. You can follow the conversation at #KidneyWk.
What do you think about these findings? Should children be included in more clinical trials, even if it means facing potential risks associated with new treatments? Given the potential severity of these diseases, how should we balance the risks and benefits of early intervention? Share your thoughts and opinions in the comments below – let's start a conversation about how to best protect the kidney health of our youngest patients!
